NIH R01 · 2024
Leveraging arginase biology against metabolic disease
ABSTRACT Intermittent fasting and caloric restriction are effective therapies against insulin resistance, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Yet, intensive lifestyle modifications are rarely sustainable. We made the provocative discovery that modulating systemic arginine status is sufficient to mimic the therapeutic effects of generalized caloric restriction on hepatic steatosis. This is clinically significant, because targeting arginine is a tractable pathway through which to treat metabolic disease. Accordingly, our long-term goal is to define the signaling cascades underlying adaptive hepatic glucose fasting, so that we can identify new…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.